Your session is about to expire
← Back to Search
Posoleucel (ALVR105) for Progressive Multifocal Leukoencephalopathy (Prevent Trial)
Prevent Trial Summary
This trial will test an allogeneic, off-the-shelf multi-virus specific T cell therapy (posoleucel) that targets six viral pathogens.
- HHV-6 Infection
- Progressive Multifocal Leukoencephalopathy
- EBV Infection
- BK Virus Infection
- Cytomegalovirus
- Adenovirus Infections
Prevent Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPrevent Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Prevent Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you please tell me how many different hospitals are a part of this research project?
"Thirteen locations are running this study, some notable ones being University of Kansas Hospital in Westwood, Stony Brook University Hospital Cancer Center in Stony Brook, and Indiana University Melvin and Bren Simon Cancer Center in Indianapolis."
Are there additional examples of research using Viralym-M Cells?
"University of Maryland Medical Center first began studying Viralym-M cells in 2021. As of now, there has only been 0 completed trials. However, 1 clinical trial is still ongoing with many studies being conducted in Westwood, Kansas."
How many people are participating in this clinical trial?
"This study is not looking for volunteers at the moment. However, it's worth noting that the clinical trial was first posted on 1/15/2021 and last updated on 5/2/2022. If you're interested in other studies, 924 trials involving cytomegalovirus infections are actively recruiting patients right now and 1 Viralym-M Cells trial is also admitting patients."
Are volunteers still needed for this experiment?
"Unfortunately, this study is not admitting patients at the moment. Although, it's worth noting that the study was first posted on 1/15/2021 and edited as recently as 5/2/2022. If you're still interested in participating in trials, there are 924 other studies currently recruiting for patients with cytomegalovirus infections and 1 trial for Viralym-M cells."
Is this the first time this type of experiment has been conducted?
"There is only one ongoing clinical trial for Viralym-M Cells in 13 cities and 1 country. The first ever study was conducted in 2021 by AlloVir. That particular research project, which reached Phases 2 & 3, had a total of 35 participants. Since that time, no other trials have been attempted."
Share this study with friends
Copy Link
Messenger